Protara Therapeutics (NASDAQ:TARA) vs. Critical Outcome Technologies (OTCMKTS:COTQF) Head-To-Head Analysis

Protara Therapeutics (NASDAQ:TARA) and Critical Outcome Technologies (OTCMKTS:COTQF) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Earnings and Valuation

This table compares Protara Therapeutics and Critical Outcome Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44 million	($1.32)	-3.89
Critical Outcome Technologies	N/A	N/A	N/A	N/A	N/A

Institutional and Insider Ownership

38.1% of Protara Therapeutics shares are held by institutional investors. 12.5% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Protara Therapeutics and Critical Outcome Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1	0	4	1	2.83
Critical Outcome Technologies	0	0	0	0	0.00

Protara Therapeutics presently has a consensus target price of $23.75, indicating a potential upside of 362.96%. Given Protara Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Protara Therapeutics is more favorable than Critical Outcome Technologies.

Profitability

This table compares Protara Therapeutics and Critical Outcome Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-36.38%	-33.81%
Critical Outcome Technologies	N/A	N/A	N/A

Summary

Protara Therapeutics beats Critical Outcome Technologies on 6 of the 8 factors compared between the two stocks.

About Protara Therapeutics

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

About Critical Outcome Technologies

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.